Expired activity
Please go to the PowerPak homepage and select a course.

Individualizing Hemophilia A Treatment: Strategies for Implementing Pharmacokinetic-Based Dosing

Jointly provided by American Academy of CME, Inc. and E&S MedEd Group, Inc.
Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals.


May 15, 2018


May 15, 2019


Hemophilia A is an X-linked congenital bleeding disorder resulting from a deficiency of Factor VIII (FVIII), often causing spontaneous bleeding into soft tissue, joints, and internal organs or excessive bleeding following injury or trauma. Significant advances in the field of hemophilia A have shifted the focus from acute, on-demand therapy to prophylaxis with the intention of maintaining adequate FVIII trough levels. Developments in treatment, such as extension of half-life and targeting of inhibitors, have been combined with novel dosing approaches that address the challenges of individual pharmacokinetics to better mimic endogenous FVIII production. Understanding these important shifts in treatment approach and strategy will better equip the members of the healthcare team to work together to improve outcomes in individuals with hemophilia A.

Faculty Educators

Surabhi Palkimas, PharmD
Pharmacy Clinical Coordinator, Hematology
University of Virginia Health System
Charlottesville, Virginia

Brenda Riske, MS, MBA, MPA
Consultant, University of Colorado Hemophilia and Thrombosis Center
Anschutz Medical Campus
Denver, Colorado

Louise M. Man, MD
Assistant Professor, Department of Medicine/Hematology/Oncology
Emily Couric Clinical Cancer Center
Charlottesville, Virginia

Learning Objectives/Outcomes

Upon completion of this educational activity, the participant should be better able to:

  1. Discuss the limitations of traditional FVIII replacement dosing strategies with regard to pharmacokinetics
  2. Review individual patient characteristics that can affect the pharmacokinetic properties of FVIII concentrates
  3. Outline strategies that can help to alleviate the burden of patient sampling and calculations required for pharmacokinetic-based dosing regimens
  4. Integrate novel extended-half-life FVIII products into individualized, pharmacokinetic-based treatment strategies

Target Audience

This initiative is intended for nursing professionals and specialty pharmacists who are involved in the management of individuals with hemophilia A.

Accreditation and Credit Designation

Nurse Practitioners and Nurses
American Academy of CME, Inc, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
American Academy of CME, Inc., designates this educational activity for 1.25 contact hours (1.25 Pharmacotherapeutic Contact Hours).

: Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.25 contact hours.

American Academy of CME, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity provides 1.25 contact hours (0.125 CEUs) of continuing education credit. ACPE Universal Activity Number 0297-9999-18-001-H01-P. Application

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Faculty Educators
Surabhi Palkimas, PharmD
Dr. Palkimas states that she no relevant financial relationship to disclose.

Brenda Riske, RN, MSN, MBA
Brenda Riske states that she serves as a Consultant (Marketing Purposes) for Genentech. She has received Grant/Research Support from CSL Behring, Shire, Bayer Foundation, Novo Nordisk, and Pfizer.  Grant for research on hemophilia utilization group studies, Principle Investigator is Dr. Mike Nichols at USC. She participates on steering committees and publications.

Louise M Man, MD
Dr. Man states that she has no relevant financial relationship to disclose.

Academy and E&S MedEd Group Planners
Laurie Ermentrout states that she has no relevant financial relationships to disclose.
John JD Juchniewicz, MCIS, CHCP, states that he has no relevant financial relationships to disclose.
Lisa Kehs states that she has no relevant financial relationships to disclose.
Natalie Kirkwood, RN, BSN, JD (Nurse Planner), states that she has no relevant financial relationships to disclose.
Lilly McVey states that she has no relevant financial relationships to disclose
Edward Moylan, RP, states that he has no relevant financial relationships to disclose.

Off-Label or Investigational Information

This activity may contain discussion of off-label or investigational information.

Disclaimer Statement

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, E&S MedEd Group, or American Nurses Credentialing Center's Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CPE credit or CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

Pharmacists: a statement of credit will be issued through CPE Monitor within 6-8 weeks. Only pharmacists who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm


For any questions, please contact: CEServices@academycme.org


© 2018. This CE-certified activity is held as copyrighted © by American Academy of CME and E&S MedEd Group, Inc. Through this notice, the Academy and E&S MedEd Group grant permission of its use for educational purposes only.

These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).